A reduction of action potentials with dexmedetomidine which was not reversed with α2-adrenergic receptor antagonists is Noted. However all studies carried out so far to prove the peripheral action of α2 agonists were animal studies. There are very few human studies, i.e. greater palatine and axillary brachial plexus nerve blocks have subsequently demonstrated that increased duration of sensory blockade can be achieved by adding dexmedetomidine to bupivacaine and levobupivacaine, respectively, by increasing the duration of analgesia with a single shot block we can achieve a longer duration of post-operative analgesia without significant clinical side-effects and hence we can avoid continuous catheterization. Hence based on the above findings the present study was planned for Comparative Assessment of Dexamethasone and Dexmedetomidine as Adjuvants to Bupivacaine in Patients Undergoing the Supraclavicular Brachial Plexus Block. Total 30 patients undergoing the hand, wrist, forearm and elbow surgeries were included in the present study. The present study was planned in Department of Anesthesia and Critical Care, Anugrah Narayan Magadh Medical College and Hospital, Gaya, Bihar, India. The study was conducted from the duration of Nov 2018 to May 2019. The data generated from the present study concludes that Dexamethasone as an adjuvant to bupivacaine in supraclavicular brachial plexus block, significantly extends the motor and sensory block duration compared to dexmedetomidine. Both adjuvants reduces postoperative morphine consumption significantly.